Could a natural peptide help lower blood pressure in obesity?

NCT ID NCT06482853

Recruiting now Disease control Sponsor: Milton S. Hershey Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing whether a naturally occurring peptide, angiotensin-(1-7), can improve blood vessel function and nerve activity in people with obesity and high blood pressure. Researchers will compare the effects of the drug against a placebo (saline) in 52 adults aged 18-65. The goal is to see if this peptide could become a new way to manage hypertension in obesity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Angiotensin-(1-7)
What this could lead to: If it works, this could point toward a new treatment option for managing high blood pressure in people with obesity.
What could go wrong: This is a very early, small study (52 people) testing a short-term infusion, so it may not lead to a lasting treatment. The drug may not show meaningful benefits or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION OBESITY

Contacts and locations

Locations

Penn State Milton S. Hershey Medical Center
RECRUITING

Hershey, Pennsylvania, 17033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.